Immune checkpoint inhibitors (ICIs) as “chemotherapy (Ctx) sensitization” strategy in advanced solid tumours

Background null The anti-tumor activity of Ctx after ICIs has been poorly investigated in patients with refractory advanced solid tumors. A recent communication suggested that ICIs may sensitize Non-Hodgkin Lymphoma to subsequent Ctx (Nicole A, Carreau et al, ASH 2019) but a control arm with exposure to alternative non-ICI therapy was missing. null null null Methods null From a prospective cohort of patients (pts) treated with ICIs (n = 310) or...